Aurinia Pharmaceuticals Non Currrent Assets Other Over Time
| AUPH Stock | USD 9.20 0.22 2.45% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aurinia Pharmaceuticals Performance and Aurinia Pharmaceuticals Correlation. Aurinia |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Currrent Assets Other Analysis
Compare Aurinia Pharmaceuticals and related stocks such as Viking Therapeutics, Axsome Therapeutics, and Madrigal Pharmaceuticals Non Currrent Assets Other Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AXSM | 42.6 K | 42.6 K | 42.6 K | 42.6 K | 42.6 K | 26.6 K | 112.8 K | 188 K | 112.3 K | 139.9 K | 317.4 K | 322.9 K | 14.7 M | 11 M | 11.6 M |
| MDGL | 82 K | 631 K | 458 K | 1.4 M | 305 K | 54.0 | 54.0 | 301 K | 227 K | 1.9 M | 1.8 M | 797 K | 1.2 M | 1.4 M | 719.9 K |
| MCRB | (266 K) | (266 K) | (266 K) | 68 K | 1.8 M | 1.5 M | 1.4 M | 1.5 M | 113 K | 1.4 M | 1.4 M | 14.6 M | 10.5 M | 50.9 M | 53.5 M |
| EXEL | 1.4 M | 2.8 M | 36.5 M | 23.8 M | 13 M | 5 M | 5.4 M | 16.7 M | 3.5 M | 11.3 M | 71.9 M | 131 M | 290.6 M | 334.2 M | 350.9 M |
| TGTX | (100 K) | 438 M | (10.4 M) | 85.1 K | 712.1 K | 750.3 K | 164.4 K | 587.3 K | 1.2 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.4 M | 1.3 M |
| BTAI | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 461 K | 51 K | 51 K | 87 K | 3.9 M | 925 K | 87 K | 82.7 K |
| SRPT | 100 K | 155 K | 2.8 M | 25 K | 2.8 M | 4.5 M | 4 M | 21.8 M | 107.3 M | 11.8 M | 13 M | 143.3 M | 286.6 M | 292 M | 306.6 M |
| HEPA | 4.2 K | 4.2 K | 4.2 K | 4.2 K | 4.2 K | 51.3 K | 70 K | 63.2 K | 127.8 K | 306.9 K | 285.1 K | 583.3 K | 426.2 K | 364.2 K | 228.6 K |
| PTCT | 297.9 K | 297.9 K | 197.1 K | 149 K | 489 K | 3.1 M | 630 K | 1.2 M | 2.3 M | 30.1 M | 60.6 M | 227.5 M | 48.6 M | 36.2 M | 34.8 M |
| TERN | 335 K | 335 K | 335 K | 335 K | 335 K | 335 K | 335 K | 335 K | 335 K | 719 K | 246 K | 94 K | 37 K | 56 K | 53.2 K |
| AKRO | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 29 K | 161 K | 417 K | 108 K | (1.0) | (0.95) |
Aurinia Pharmaceuticals and related stocks such as Viking Therapeutics, Axsome Therapeutics, and Madrigal Pharmaceuticals Non Currrent Assets Other description
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.My Equities
My Current Equities and Potential Positions
| Aurinia Pharmaceuticals | AUPH |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | British Columbia; Canada |
| Exchange | NASDAQ Exchange |
USD 9.2
Check out Aurinia Pharmaceuticals Performance and Aurinia Pharmaceuticals Correlation. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Aurinia Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.